Publicaciones en las que colabora con José Luis Labandeira García (48)

2024

  1. Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models

    Stem Cell Research and Therapy, Vol. 15, Núm. 1

2023

  1. Combined cell-based therapy strategies for the treatment of Parkinson's disease: Focus on mesenchymal stromal cells

    Neural Regeneration Research, Vol. 18, Núm. 3, pp. 478-484

2021

  1. Dopamine regulates adult neurogenesis in the ventricular-subventricular zone via dopamine D3 angiotensin type 2 receptor interactions

    Stem Cells, Vol. 39, Núm. 12, pp. 1778-1794

  2. Dose-dependent effect of mesenchymal stromal cells co-grafted with dopaminergic neurons in a Parkinson's disease rat model

    Journal of Cellular and Molecular Medicine, Vol. 25, Núm. 20, pp. 9884-9889

  3. Nrf2 activation and downstream effects: Focus on parkinson’s disease and brain angiotensin

    Antioxidants, Vol. 10, Núm. 11

2019

  1. Interaction between Angiotensin Type 1, Type 2, and Mas Receptors to Regulate Adult Neurogenesis in the Brain Ventricular-Subventricular Zone

    Cells, Vol. 8, Núm. 12

2018

  1. Angiotensin II induces oxidative stress and upregulates neuroprotective signaling from the NRF2 and KLF9 pathway in dopaminergic cells

    Free Radical Biology and Medicine, Vol. 129, pp. 394-406

  2. Data on the effect of Angiotensin II and 6-hydroxydopamine on reactive oxygen species production, antioxidant gene expression and viability of different neuronal cell lines

    Data in Brief

  3. Prostaglandin EP2 Receptors Mediate Mesenchymal Stromal Cell-Neuroprotective Effects on Dopaminergic Neurons

    Molecular Neurobiology, Vol. 55, Núm. 6, pp. 4763-4776

2017

  1. Brain renin-angiotensin system and microglial polarization: Implications for aging and neurodegeneration

    Frontiers in Aging Neuroscience, Vol. 9, Núm. MAY

  2. Laser capture microdissection protocol for gene expression analysis in the brain

    Histochemistry and Cell Biology, Vol. 148, Núm. 3, pp. 299-311

2016

  1. Effects of rho kinase inhibitors on grafts of dopaminergic cell precursors in a rat model of Parkinson’s disease

    Stem Cells Translational Medicine, Vol. 5, Núm. 6, pp. 804-815

2015

  1. Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation

    GLIA, Vol. 63, Núm. 3, pp. 466-482

  2. Reciprocal regulation between sirtuin-1 and angiotensin-II in the substantia nigra: Implications for aging and neurodegeneration

    Oncotarget, Vol. 6, Núm. 29, pp. 26675-26689

2014

  1. Brain renin-angiotensin system and dopaminergic cell vulnerability

    Frontiers in Neuroanatomy, Vol. 8, Núm. JULY

2013

  1. Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells

    Experimental Neurology, Vol. 250, pp. 384-396

  2. Dopamine-Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease

    Movement Disorders, Vol. 28, Núm. 10, pp. 1337-1342

2012

  1. 2-Benzazepine nitrones protect dopaminergic neurons against 6-hydroxydopamine-induced oxidative toxicity

    Archiv der Pharmazie, Vol. 345, Núm. 8, pp. 598-609

  2. Brain angiotensin and dopaminergic degeneration: Relevance to Parkinson’s disease

    American Journal of Neurodegenerative Diseases, Vol. 1, Núm. 3, pp. 226-244

  3. Cografting of carotid body cells improves the long-term survival, fiber outgrowth and functional effects of grafted dopaminergic neurons

    Regenerative Medicine, Vol. 7, Núm. 3, pp. 309-322